Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. (26th July 2021)

• Record Type: Journal Article
• Authors: Sedano, Rocio; Hogan, Malcolm; Nguyen, Tran M; Chang, Joshua; Zou, G Y; Macdonald, John K; Vande Casteele, Niels; Hanzel, Jurij; Crowley, Eileen; Battat, Robert; Dulai, Parambir S; Singh, Siddharth; D'Haens, Geert; Sandborn, William; Feagan, Brian G; Ma, Christopher; Jairath, Vipul
• Is Part Of: Journal of Crohn's and colitis. Volume 16:Number 2(2022)
• Page Start: 224
• Page End: 243
• Publication Date: 2021-07-26
• Subjects: Ulcerative colitis -- clinical trials -- placebo; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjab135
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background and Aims: Quantifying placebo rates and the factors influencing them are essential to inform trial design. We provide a contemporary summary of clinical, endoscopic, histological and safety placebo rates in induction and maintenance clinical trials of ulcerative colitis, and identify factors influencing them. Methods: MEDLINE, EMBASE and the Cochrane library were searched from April 2014 to April 2020, updating a prior meta-analysis that searched from inception to April 2014. We included placebo-controlled trials of aminosalicylates, corticosteroids, immunosuppressives, small-molecules and biologics in adults with ulcerative colitis. Placebo rates were pooled using random-effects and mixed-effects meta-regression models to assess the associated study-level. Results: In 119 trials [92 induction, 27 maintenance] clinical, endoscopic and histological remission placebo rates for induction trials were 11% (95% confidence interval [CI] 9–13%), 19% [95% CI 15–23%] and 15% [95% CI 11–19%], respectively; for maintenance trials, clinical and endoscopic placebo remission rates were 18% [95% CI 12–25%] and 20% [95% CI 15–25%], respectively. Higher endoscopic subscore and a higher rate of exposure to prior biologic therapy at enrolment were associated with lower clinical and endoscopic placebo remission rates. Absence of central reading was associated with an increase in placebo endoscopic response and remission rates. More follow-up visits and increasing trial duration were associated with higher clinical placebo rates. Conclusions: Placebo rates in ulcerative colitis trials vary according to the endpoint assessed, whether it is for assessment of response or remission, and whether the trial is designed for induction or maintenance. These contemporary rates across different endpoints and drug classes will help to inform trial design.